Clinical Trial Goal
To find out:
- The highest dose of loncastuximab tesirine that's safe to give with venetoclax
- If the combination of loncastuximab tesirine and venetoclax is safe and works well to treat NHL that has relapsed or is refractory
You may be able to join this trial if you:
- Are 18 years or older
- Have NHL that has relapsed or is refractory. Some examples include:
- Diffuse large B-cell lymphoma (DLBCL)
- Follicular lymphoma
- Indolent lymphoma
- Mantle cell lymphoma (MCL)
- Marginal zone lymphoma (MZL)
- Mediastinal large B-cell lymphoma
- Richter's transformation
- Have not had allogeneic (cells from a donor) blood or marrow transplant (BMT) in the last 3 months
- Do not have graft versus host disease (GVHD)
- Agree to have other standard tests done to see if you can be in the clinical trial
Trial Details
Loncastuximab tesirine is a monoclonal antibody-drug conjugate that targets CD19 on certain cells.
Venetoclax is a small molecule inhibitor that blocks BCL2 in certain cells.
You’ll get treatment in cycles that last 3 weeks. In each cycle, you'll get:
Venetoclax is a small molecule inhibitor that blocks BCL2 in certain cells.
You’ll get treatment in cycles that last 3 weeks. In each cycle, you'll get:
- Loncastuximab tesirine – Given as an intravenous (IV) infusion 1 time
- Venetoclax – A pill that you take by mouth 1 time each day for 5 to 7 days
You'll have scans to see how well the treatment is working. The clinical trial doctors will check your health for up to 1 year.
The Food and Drug Administration (FDA) has approved all of the drugs used in this trial. Using them in this way to treat NHL that has relapsed or is refractory is new and unproven.
Locations
Cleveland Clinic Taussig Cancer Center, Case Comprehensive Cancer CenterRECRUITING
Cleveland, Ohio
Paolo Caimi, MD, 1-866-223-8100, TaussigResearch@ccf.org
Sponsors
lead: Paolo Caimi, MD
